Michele Aquilano has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of BRCA in patients undergoing abiraterone ± stereotactic body radiotherapy: the ARTO trial

    by Giulio Francolini, Vanessa Di Cataldo, Pietro Garlatti, Niccolò Bertini, Michele Aquilano, Saverio Caini, Gianluca Ingrosso, Alessio Bruni, Rolando Maria D’ANgelillo, Luca Tagliaferri, et al.

  • Re-irradiation in patients affected by prostate cancer and relapsing after previous definitive or postoperative radiotherapy. An international registry based study on behalf of Italian association of radiotherapy and clinical oncology (AIRO). (RE-START)

    by Giulio Francolini, Vanessa Di Cataldo, Saverio Caini, Barbara A Jereczek-Fossa, Giulia Marvaso, Federico Mastroleo, Eugenio Cammareri, Daniela Alterio, Marcin Miszczyk, Wojciech Majewski, et al.


  • Open Access

    Integrating Radiomics and Artificial Intelligence (AI) in Stereotactic Body Radiotherapy (SBRT)/Stereotactic Radiosurgery (SRS): Predictive Tools for Tailored Cancer Care

    by Ilaria Morelli, Marco Banini, Daniela Greto, Luca Visani, Pietro Garlatti, Mauro Loi, Michele Aquilano, Marianna Valzano, Viola Salvestrini, Niccolò Bertini, et al.

    Purpose: This systematic review aims to analyze the literature on the application of AI in predicting patient outcomes and treatment-related toxicity in those undergoing SBRT or SRS across heterogeneous tumor sites. Materials and methods: Our review conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. PubMed, EMBASE and Scopus were systematically searched for English-language human studies evaluating AI for outcome and toxicity prediction in patients undergoing SBRT or SRS for solid tumors. Search terms included (“Stereotactic Body Radiotherapy” OR “SBRT” OR “Stereotactic Radiosurgery” OR “SRS” OR “Stereotactic Ablative Radiotherapy” OR “SABR”) AND (“Artificial Intelligence” OR “AI” OR “Machine Learning” OR “Deep Learning” OR “Radiomics”) AND (“Response Prediction” OR “Response to Treatment” OR “Outcome Prediction”) AND (“Toxicity” OR “Side Effects” OR “Treatment Toxicities” OR “Adverse Events”). Results: The search yielded 29 eligible retrospective studies, published between 2020 and 2025. Eight studies addressed early-stage primary lung cancer, highlighting the potential of AI-based models in predicting radiation-induced pneumonitis, fibrosis and local control. Five studies investigated AI models for predicting hepatobiliary toxicity following SBRT for liver tumors. Sixteen studies involved SRS-treated patients with brain metastases or benign intracranial neoplasms (e.g., arteriovenous malformations, vestibular schwannomas, meningiomas), exploring AI algorithms for predicting treatment response and radiation-induced changes. In the results, AI might have been exploited to both reaffirm already known clinical predictors and to identify novel imaging, dosimetric or biological biomarkers. Examples include predicting radiation pneumonitis in lung cancer, residual liver function in hepatic tumors and local recurrence in brain metastases, thus supporting tailored treatment decisions. Conclusions: Combining AI with SBRT could greatly enhance personalized cancer care by predicting patient-specific outcomes and toxicity. AI models analyze complex datasets, including imaging and clinical data, to identify patterns that traditional methods may miss, thus enabling more accurate risk stratification and reducing variability in treatment planning. With further research and clinical validation, this integration could make radiotherapy safer, more effective and contribute to advancement in precision oncology.


  • Open Access

    Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence After Prostatectomy: STARR (NCT05455736): An Early Analysis from the STARR Trial

    by Niccolo’ Bertini, Giulio Francolini, Vanessa Di Cataldo, Pietro Garlatti, Michele Aquilano, Giulio Frosini, Olga Ruggieri, Laura Masi, Raffaela Doro, Mauro Loi, et al.

    Purpose/Objectives: Salvage radiotherapy (SRT) after a radical prostatectomy is a curative approach for patients with biochemical recurrence (BR). However, outcomes are often less favorable when imaging reveals macroscopic local recurrence. In such cases, dose escalation through stereotactic salvage radiotherapy (SSRT) may offer improved disease control. The STARR trial (NCT05455736) is a prospective, multicenter study evaluating the efficacy and safety of SSRT in patients with macroscopic prostate bed recurrence. This interim analysis reports early findings from the initial patient cohort. Materials and Methods: Patients with BR (PSA > 0.2 ng/mL) post-prostatectomy and PET-confirmed macroscopic recurrence (PSMA or Choline PET, confirmed by MRI) were eligible. Treatment involved CyberKnife®-based SSRT delivering 35 Gy in five fractions to the visible lesion. Androgen deprivation therapy (ADT) was not permitted. Complete biochemical response (CBR) was defined as PSA < 0.2 ng/mL, and biochemical response (BR) as a ≥50% PSA reduction. Additional outcomes included biochemical, radiological, and ADT-free survival (bPFS, rPFS, aPFS). Results: As of analysis, 51 patients were enrolled, with a median follow-up of 16 months (95% CI: 16–22). CBR and BR were achieved in 45.1% and 80.4% of patients, respectively. Events affecting bPFS, rPFS, and aPFS occurred in 12, 5, and 6 patients, with median values not yet reached. Toxicity was minimal, with two cases each of acute grade 2 GI and GU events, and one late grade 2 GI event. No grade ≥ 3 toxicities were reported. Conclusion: Early data support SSRT as a safe and a promising option for macroscopic local recurrence, with encouraging response rates and minimal toxicity.


  • PO-1865 Benefit of daily online cbct-based adaptive radiotherapy in prostate cancer: a preliminary analysis.

    by A. D'Aviero, M. Aquilano, A. Boschetti, F. Catucci, P. Gaias, F. Gruosso, M. Iezzi, M. Marras, S. Menna, D. Piccari, et al.

  • Barrier Films and Dressings for the Prevention of Acute Radiation Dermatitis: A Systematic Review and Meta-Analysis

    by Jolien Robijns, Michele Aquilano, Suvam Banerjee, Saverio Caini, Julie Ryan Wolf, Corina van Den Hurk, Mara Beveridge, Henry Lam, Pierluigi Bonomo, Edward Chow, et al.

    Purpose This systematic review and meta-analysis aimed to evaluate the efficacy of barrier films and dressings in preventing acute radiation dermatitis (RD). Methods OVID Medline, Embase, and Cochrane databases were searched from 1946 to September 2020 to identify randomized controlled trials on the use of barrier films or dressings to prevent RD. For comparable outcomes between studies, pooled effect sizes and 95% confidence intervals (CI) were calculated using the random effects analysis in RevMan 5.4. Results Fourteen and 11 studies were included in the qualitative and quantitative analyses, respectively. Five types of barrier films used for RD were identified: Hydrofilm, StrataXRT®, Mepitel® Film, 3 M™ Cavilon™ No-Sting Barrier Film, and silver leaf nylon dressing. Hydrofilm and Mepitel Film significantly reduced the development of RD grade ≥ 2 in breast and head and neck cancer patients (RR 0.32, 95%CI 0.19, 0.56, p < 0.0001; RR 0.21, 95%CI 0.05, 0.89, p = 0.03, resp.). Moreover, Hydrofilm had a beneficial effect on patient-reported outcomes (PROs) (SMD -0.75, 95%CI -1.2, -0.29, p = 0.001). The meta-analyses on the other barrier films did not show any significant effect. Conclusion This review and meta-analysis demonstrated that Hydrofilm and Mepitel Film could effectively reduce RD severity and improve PROs. The evidence is generally weak for all the studies on barrier films and dressings due to a limited study number, high risk of bias, small sample sizes, and minimal comparable outcome measures. It’s potential has been proven, but future research in this field is recommended to confirm the efficacy of these products and assess real-world feasibility.


  • Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?

    by Michele Aquilano, Mauro Loi, Luca Visani, Lorenzo Livi, Joost J. Nuyttens

    Oligoprogression (OPD) is defined as a condition where limited progression (1–3 metastases) is observed in patients undergoing systemic cancer treatment. In this study we investigated the impact of...

  • Open Access

    A narrative review of postoperative adjuvant radiotherapy for non-small-cell lung cancer

    by Emanuela Olmetto, Marco Perna, Cecilia Cerbai, Michele Aquilano, Marco Banini, Matteo Mariotti, Lorenzo Livi, Vieri Scotti

    A narrative review of postoperative adjuvant radiotherapy for non-small-cell lung cancer Emanuela Olmetto, Marco Perna, Cecilia Cerbai, Michele Aquilano, Marco Banini, Matteo Mariotti, Lorenzo Livi, Vieri Scotti